Withdrawal of cefoperazone with milk after intramammary administration in dairy cows – prospective and retrospective analysis

Open access


The aim of the study was to carry out retrospective and prospective comparative analyses of the pharmacokinetics of CEF after single intramammary (IMM) administration in cows. The prospective study (study A) was conducted on 9 dairy cows of the Polish Black-White race with clinical mastitis during the lactation period. Milk samples were collected at 2, 4, 6, 8, 10, 24, 36, 48, 72 and 84 h after single IMM administration of 250 mg of CEF to one quarter. Drug concentrations in milk samples were determined by HPLC-MS/MS technique and the results of the pharmacokinetic analysis were compared to those obtained in previous studies based on the microbiological (study B) and HPLC-UV methods (study C and D). Pharmacokinetic parameters were calculated based on adapted two-compartment model of drug distribution. One of the findings of the comparison of the analysed investigations is that the CEF kinetics determined with the microbiological method is consistent with the results obtained by the authors of this paper. Both studies yielded similar results of the key pharmacokinetic parameters related to the level of the drug distribution to tissues and elimination half-life. In the pharmacodynamic analysis, the observations in all four studies were entirely consistent and have shown lower values of T>MIC90 in healthy animals and significantly higher values in infected dairy cows. The comparison of studies A, B, C, and D revealed that the time of complete CEF wash-out of 90.90% varied and amounted to 5.7, 8.0, 2.2, and 2.2 days after administration of the drug, respectively.

It was confirmed that not only the type of the analytical method but also correct sampling have a significant impact on determination of the correct value of the drug half-life after IMM administration. The comparative analysis of studies in which the milk yield was high and low allows a conclusion that this parameter in the case of CEF has no significant effect on T>MIC90.

Błądek T, Posyniak A, Gajda A, Gbylik M, Żmudzki J (2011) Multi-class procedure for analysis of antibacterial compounds in animal tissues by liquid chromatographytandem mass spectrometry. Bull Vet Inst Pulawy 55: 741-748.

Bozhkova G, Angelov L, Danov M (1983) Cefacetril in treatment of clinical bovine mastitis. Vet Med Nauki 20: 68-75.

Bradley AJ (2002) Bovine mastitis: an evolving disease. Vet J 164:116-128.

Burmańczuk A, Roliński Z, Kowalski C, Zań R (2011) Concentration of cefacetril in milk after its intramammary administration to cows with healthy and inflammed mammary gland. Bull Vet Inst Pulawy 55: 685-688.

Cagnardi P, Villa R, Gallo M, Locatelli C, Carli S, Moroni P, Zonca A (2010) Cefoperazone sodium preparation behavior after intramammary administration in healthy and infected cows. J Dairy Sci 93: 4105-4110.

Codex Alimentarius Commission (2016) Food and Agriculture Organization of the United Nations. World Health Organization. Rome, Italy. http://www.fao.org/fao-who-codexalimentarius/standards/en/

Concordet D, Toutain PL (1997) The withdrawal time estimation of veterinary drugs revisited. J Vet Pharmacol Ther 20: 380-386.

Costa EO, Ribeiro AR, Watanabe ET, Melville PA (1998) Infectious bovine mastitis caused by environmental organisms. Zentralbl Veterinarmed B 45: 65-71.

Daeseleire E, De Ruyck H, Van Renterghem R (2000) Confirmatory assay for the simultaneous detection of penicillins and cephalosporins in milk using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 14: 1404-1409.

De Brito RB, Junqueira RG (2006) Determination of Beta-Lactam Residues in Milk by High Performance Liquid Chromatography. Braz Arch Biol Technol 49: 41-46.

EC (European Commission) (2002) Commission Decision 2002/657/EC of 12 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. Off J Eur Commun L 221: 8-36. http://eur-lex.europa.eu/eli/dec/2002/657/oj

EMA (1998) Committee for veterinary medicinal products cefoperazone Summary Report. EMEA/MRL/512/98-FINAL. http://www.ema.europa.eu/

FDA (2012) 21 CFR Part 530 [Docket No. FDA-2008-N-0326] New Animal Drugs. Cephalosporin Drugs. Extralabel Animal Drug Use. Order of Prohibition 735-744. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295364/

Gibaldi M, Perrier D (1982) Pharmacokinetics. 2nd ed. Marcel Dekker, New York.

Grabowski T, Marczak M, Jaroszewski JJ, Whitmire M (2012) Comparison of bioequivalence study regulatory requirements for human and veterinary drugs. Regul Toxicol Pharmacol 64: 233-242.

Gruet P, Maincent P, Berthelot X, Kaltsatos V (2001) Bovine mastitis and intramammary drug delivery: review and perspectives. Adv Drug Deliv Rev 50: 245-259.

Guerrini VH, Filippich LJ, Cao GR, English PB, Bourne DW (1985) Pharmacokinetics of cefaronide, ceftriaxone, and cefoperazone in sheep. J Vet Pharmacol Ther 8: 120-127.

Guterbock WW, Van Eenennaam AL, Anderson RJ, Gardner IA, Cullor JS, Holmberg CA (1993) Efficacy of intramammary antibiotic therapy for treatment of clinical mastitis caused by environmental pathogens. J Dairy Sci 76: 3437-3444.

Heringstad B, Klemetsdal G, Ruane J (2000) Selection for mastitis resistance in dairy cattle: a review with focus on the situation in the Nordic countries. Livest Prod Sci 64: 95-106.

Malinowski E, Kłosowska A, Lassa H (2001) Variability among etiological agents of clinical mastitis in cows. Pol J Vet Sci 4: 41-44.

Novelli A, Fallani S, Cassetta MI, Conti S (2000) Pharmacokinetics and pharmacodynamics of oral cephalosporins as critical factors in choice of antibiotics. Int J Antimicrob Agents 16: 501-505.

Rossitto PV, Ruiz L, Kikuchi Y, Glenn K, Luiz K, Watts JL, Cullor JS (2002) Antibiotic susceptibility patterns for environmental streptococci isolated from mastitis in central California dairies. J Dairy Sci 85: 132-138.

Samanidou VF, Hapeshi EA, Papadoyannis IN (2003) Rapid and sensitive high-performance liquid chromatographic determination of four cephalosporin antibiotics in pharmaceuticals and body fluids. J Chromatogr B 788: 147-158.

Sanders WE Jr, Sanders CC (1988) Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 10: 830-838.

Van Eenennaam AL, Gardner IA, Holmes J, Perani L, Anderson RJ, Cullor JS, Guterbock WM (1995) Financial analysis of alternative treatments for clinical mastitis associated with environmental pathogens. J Dairy Sci 78: 2086-2095.

Watts JL, Salmon SA (1997) Activity of selected antimicrobial agents against strains of Staphylococcus aureus isolated from bovine intramammary infections that produce beta-lactamase. J Dairy Sci 80: 788-791.

Wilson CD, Gilbert GA (1986) Pharmacokinetics of cefoperazone in the cow by the intramammary route and its effect on mastitis pathogens in vitro. Vet Rec 118: 607-609.

Polish Journal of Veterinary Sciences

The Journal of Committee of Veterinary Sciences of Polish Academy of Sciences and University of Warmia and Mazury in Olsztyn

Journal Information

IMPACT FACTOR 2016: 0.697
5-year IMPACT FACTOR: 0.773

CiteScore 2016: 0.73

SCImago Journal Rank (SJR) 2016: 0.315
Source Normalized Impact per Paper (SNIP) 2016: 0.486


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 209 168 8
PDF Downloads 121 109 5